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A B S T R A C T
Background: A high prevalence of primary bile acid diarrhoea (BAD) has been reported for Rome III defined
irritable bowel syndrome (IBS)-diarrhoea and functional diarrhoea. We determined whether this still applies
under the contemporaneous Rome IV criteria, given that the latter characterises IBS-diarrhoea as having
more frequent abdominal pain compared with previous iterations, whilst no longer recognising abdominal
discomfort.
Methods: Patients referred for a 75SeHCAT test completed a baseline questionnaire comprising, i) demo-
graphic data, ii) risk factors for BAD (inflammatory bowel disease, bowel resection, cholecystectomy, micro-
scopic colitis, celiac disease, abdominal-pelvic radiotherapy), iii) the Rome III and IV bowel disorder
questionnaire, and iv) mood and somatisation scores. A diagnosis of BAD constituted a 75SeHCAT of 15%,
with moderate to severe disease being defined as 10% and 5%, respectively.
Findings: Of 300 patients with complete dataset, 184 had no risk factors for BAD and fulfilled criteria for
either IBS-diarrhoea or functional diarrhoea. The prevalence of primary BAD was 38% (n = 70/184), with
almost half having moderate (n = 16) to severe (n = 17) disease. Using the Rome III criteria, the prevalence of
primary BAD was 36% in IBS-diarrhoea (n = 63/173) and 64% (n = 7/11) in functional diarrhoea; p = 0.11. Using
the Rome IV criteria, the prevalence of primary BAD was 38% (n = 53/139) in IBS-diarrhoea and 38% (n = 17/
45) in functional diarrhoea; p = 0.97. Patients with primary BAD experienced more frequent loose stools
(p = 0.01) and had a higher body mass index (p<0.0001) compared to those without BAD, but otherwise no
significant differences were seen in age, gender, mood, somatisation, or abdominal pain. The presence of pri-
mary BAD in patients classified as overweight or obese was approximately 40% and 60%, respectively.
Interpretation: Over a third of patients with Rome IV IBS-diarrhoea or functional diarrhoea have primary BAD,
similar to Rome III. We therefore recommend that, in secondary care settings, generic testing for primary
BAD should be considered in patients presenting with chronic diarrhoea of presumed functional origin
regardless of concomitant abdominal pain. Centres that lack tests for primary BAD, and who empirically treat
instead, may consider targeting patients who are overweight or obese.
© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
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1. Introduction
Bile acids are synthesised in the liver, stored in the gallbladder,
and released into the small intestine, where they aid digestion of lip-
ids. Normally, 95% of bile acids are reabsorbed in the terminal ileum
and recycled back to the liver via the entero-hepatic circulation. If
there is a failure of reabsorption, excess bile acids spill over into the
colon where they stimulate electrolyte and water secretion, resulting
in chronic watery diarrhoea [1,2]. The concept of bile acid diarrhoea
(BAD) being responsible for symptom generation is supported by
colonic bile acid exposure correlating with colonic transit time and
bowel habit, with subsequent treatment with bile acid sequestrants
leading to clinical improvement [3]. The conditions causing BAD can
be classified according to the aetiology. Secondary BAD relates to the
malabsorption of bile acids from the terminal ileum (previously
termed Type 1 BAD) due to either resection or localised disease (e.g.
Crohn’s disease, right hemicolectomy). It also encompasses
* Corresponding author at: Academic Department of Gastroenterology, Sheffield
Teaching Hospitals, Sheffield, United Kingdom.
E-mail address: imran.aziz1@nhs.net (I. Aziz).
https://doi.org/10.1016/j.eclinm.2020.100465
2589-5370/© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
ARTICLE IN PRESS
JID: ECLINM [m5G;July 15, 2020;1:51]
Please cite this article as: M.G. Shiha et al., High prevalence of primary bile acid diarrhoea in patients with functional diarrhoea and irritable
bowel syndrome-diarrhoea, based on Rome III and Rome IV criteria, EClinicalMedicine (2020), https://doi.org/10.1016/j.eclinm.2020.100465
EClinicalMedicine 000 (2020) 100465
Contents lists available at ScienceDirect
EClinicalMedicine
journal homepage: https://www.journals.elsevier.com/eclinicalmedicine
miscellaneous intestinal disorders such as previous cholecystectomy,
coeliac disease, microscopic colitis, or fibrosis following abdominal-
pelvic radiotherapy (previously termed Type 3 BAD). Primary BAD -
otherwise known as Type 2 BAD or idiopathic BAD - is where there is
no anatomical abnormality or other risk factors apparent [1,2]. In the
latter case, evidence suggests that absorption of bile acids within the
terminal ileum is normal or increased [4], but impaired negative
feedback of bile acids on fibroblast growth factor (FGF)19 leads to
dysregulation of the enterohepatic circulation and excessive bile acid
synthesis [5].
A systematic review and meta-analysis has shown that between a
quarter to a third of cases with chronic diarrhoea of presumed func-
tional origin - i.e. diagnosed as irritable bowel syndrome with diar-
rhoea (IBS-diarrhoea) or functional diarrhoea - actually have primary
BAD [6]. As such, recent guidelines from the United Kingdom, Canada,
and United States recommend testing (where possible) for primary
BAD in patients with suspected IBS-diarrhoea or functional diarrhoea
[79]. However, this guidance is based upon data derived using the
historic Rome I-III criteria for IBS-diarrhoea and functional diarrhoea
which, following the recent publication of the Rome IV criteria in
2016, have undergone substantial modifications [10]. Whilst the pre-
vious Rome III criteria were relatively lax and defined the symptoms
of IBS as abdominal pain or discomfort at least 23 days a month
associated with altered bowel habit, the Rome IV criteria for IBS are
far more stringent in that discomfort is no longer a recognised term
whilst abdominal pain frequency has increased to at least one day
per week [10]. Consequently, a proportion of patients previously ful-
filling criteria for IBS-diarrhoea under the Rome III criteria will no
longer satisfy criteria for IBS-diarrhoea under the Rome IV criteria,
and instead be allocated a diagnosis of functional diarrhoea [11].
Following this update in criteria, it may be envisaged that the
prevalence of primary BAD will still remain high for patients with
Rome IV functional diarrhoea. However, whether primary BAD can
present as a painful disorder and thus mimic Rome IV IBS-diarrhoea
is less clear. By means of its nomenclature, some physicians may
merely view primary BAD as a relatively painless diarrhoeal disorder,
a concept that would be supported by data showing primary BAD to
be associated with rectal hyposensitivity and without any association
for abdominal pain [3,12]. In contrast, a few small studies have dem-
onstrated colonic bile acids to correlate positively with visceral
hypersensitivity and abdominal pain intensity [13,14]. In view of this
discrepant data, large studies to confirm a possible association
between primary BAD and abdominal pain are needed, with the
Rome IV criteria for IBS-diarrhoea and functional diarrhoea providing
an opportunity to study this from a clinically meaningful perspective.
Hence, our primary aim was to determine whether the high prev-
alence of primary BAD reported for Rome III defined IBS-diarrhoea
and functional diarrhoea is still applicable using the contemporane-
ous Rome IV criteria. Secondary outcomes were to identify any clini-
cal characteristics that may be predictive of primary BAD.
2. Methods
2.1. Study design and participants
This observational study was undertaken at Sheffield Teaching
Hospitals, United Kingdom, during the course of 2019. The hospital
provides secondary care services to a local population of 500,000
people. All adults, aged 18 years and over, referred at the clinical dis-
cretion of their GI physician to the Nuclear Medicine department to
test for the possibility of BAD were eligible to participate. Individuals
were invited to complete a baseline questionnaire collecting demo-
graphic and symptom-based data, followed by undergoing a 75Sele-
nium HomoCholic Acid Taurine (75SeHCAT) retention test to assess
for BAD.
Baseline questionnaire - The following items were collected on
the day of the 75SeHCAT retention test:
a) Demographic data  participants entered their age, sex, ethnic-
ity, alcohol and tobacco use, and weight in kg and height in
metres which was subsequently used to calculated body mass
index (BMI). This was further classified in accordance with the
World Health Organization criteria as underweight (<18.5), nor-
mal weight (18.524.9), overweight (2529.9) and obese (30)
[15].
b) Past medical history patients were asked whether they had any
of the following illnesses or interventions; inflammatory bowel
disease, celiac disease, microscopic colitis, cholecystectomy,
bowel resection, or abdominal-pelvic radiotherapy. For verifica-
tion, all clinical records were reviewed.
Research in the context
Evidence before this study
Almost a third of patients presenting with symptoms compati-
ble with functional diarrhoea or IBS-diarrhoea have primary
bile acid diarrhoea (BAD). However, this data has been based
on historic Rome I-III criteria. The Rome IV criteria, published in
2016, have undergone marked modifications with IBS now
stringently defined as a chronic bowel disorder associated with
frequent abdominal pain. Whether primary BAD can present as
a painful bowel disorder, and therefore mimic the symptoms of
Rome IV IBS-diarrhoea is not known. A few small studies dem-
onstrate that colonic bile acids correlate positively with visceral
hypersensitivity and the intensity of abdominal pain, whilst
others report visceral hyposensitivity and no association with
abdominal pain. Hence, evaluating the prevalence of primary
BAD in patients with Rome IV functional diarrhoea and IBS-
diarrhoea will help provide clinicians with clarity in whom to
test. It will also aid in understanding the association between
primary BAD and abdominal pain.
Added value of this study
Over a third of subjects with Rome IV defined IBS-diarrhoea or
functional diarrhoea have primary BAD, as defined by a 75Sele-
nium HomoCholic Acid Taurine (75SeHCAT) test of 15%. This is
similar to the Rome III criteria. Moreover, almost half of those
with primary BAD have moderate to severe disease. There was
no correlation between abdominal pain frequency and primary
BAD. Primary BAD was associated with increased body mass
index, with 40% of overweight and 60% of individuals with obe-
sity having an abnormal 75SeHCAT test, compared with around
20% who were of normal weight.
Implications of all the available evidence
Primary BAD commonly mimics the symptoms of Rome IV IBS-
diarrhoea and functional diarrhoea, and therefore should be
tested for in patients with chronic diarrhoea irrespective of
abdominal pain. These findings support and update recent
guidelines from the United Kingdom, Canada, and the United
States which are promoting an increased awareness of primary
BAD. Centres who currently do not have the facilities to test for
BAD, but empirically treat with bile acid sequestrants instead,
may consider targeting individuals who are overweight or
obese. Randomised controlled trials of therapies for primary
BAD need to performed, including whether obesity manage-
ment could be an option
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c) Mood and somatisation data  individuals with bowel symp-
toms, in particular those of functional origin, can exhibit psycho-
logical distress and somatic symptoms [16]. To collect
information on psychological distress we used the hospital anxi-
ety and depression scale (HADS), which is a 14-item instrument
containing 7 questions for anxiety and 7 questions for depression
[17]. Each question is scored from 0 to 3, providing a minimum
score of 0 (no symptoms) and a maximum score of 21 (maximal
severity of symptoms) on each subscale. A subscale score of 11
is used to indicate a clinically significant level of anxiety or
depression.
The Patient Health Questionnaire (PHQ)12 evaluates the severity of
extra-intestinal somatic symptoms [18]. The twelve non-GI symp-
toms assessed are back pain, limb pain, headaches, chest pain, dizzi-
ness, fainting spells, palpitations, breathlessness, menstrual cramps,
dyspareunia, insomnia and lethargy. Each item is scored from 0 to 2,
with the total score ranging from 0 to 24, and high levels of somatisa-
tion categorised as a PHQ-12 score 13.
d) The Rome III/IV bowel disorder questionnaire [19]  Participants
were asked to score the frequency of mushy or watery loose
stools over the last 3 months, with answers ranging from 0% 
and increasing by 10% increments  to a maximum score of
100%. Mushy and loose stools denote type 6 and type 7 on the
Bristol Stool form scale [10], respectively, with the Rome bowel
disorder questionnaire collecting this information as a single
item [19].
Subjects were also asked to complete two separate questions to
ascertain the presence of abdominal discomfort and abdominal pain,
respectively. Specifically, patients were asked a) “In the last 3
months, how often did you have discomfort anywhere in your abdo-
men?” and b) “In the last 3 months how often did you have pain any-
where in your abdomen?” The answers available for these questions
were: never, fewer than 1 day a month, 1 day a month, 23 days a
month, 1 day a week, 23 days a week, most days, everyday, multiple
times per day or all the time.
Based on these answers  and in the absence of organic disease - it
was possible to identify which subjects fulfilled Rome III/IV criteria
for IBS-diarrhoea and functional diarrhoea. To satisfy Rome III criteria
for IBS-diarrhoea, subjects recorded having abdominal pain or dis-
comfort at least 23 days a month, with the others deemed to have
Rome III functional diarrhoea. In contrast, to satisfy Rome IV criteria
for IBS-diarrhoea, patients would record having abdominal pain at
least 1 day per week, with the remaining classed as Rome IV func-
tional diarrhoea.
The 75SeHCAT retention test - This is a simple and highly sensitive
method of testing for BAD, where retention of radio-labelled bile
acids of less than 15% after 7 days is abnormal. The degree of BAD can
be further classified as mild if retention 15%, moderate if 10%, and
severe if 5%. The results of the 75SeHCAT retention tests were
reported by the Nuclear Medicine department who were blinded to
the questionnaire data.
2.2. Statistical analysis
The primary analysis determined the prevalence of primary BAD
in patients with symptoms compatible with functional diarrhoea and
IBS-diarrhoea, according to the Rome III and Rome IV criteria. We
also compared difference in characteristics in those with primary
BAD versus those without, whilst also extending to compare charac-
teristics across mild, moderate, and severe BAD. Finally, we deter-
mined the association between the frequency of abdominal pain and
the prevalence of primary BAD.
Statistical analysis was carried out using SPSS version 25.0 soft-
ware, with significance set at a p-value of <0.05. Categorical variables
were summarised by descriptive statistics, including total numbers
and percentages, with comparisons between groups performed using
the chi-square test or Fisher exact test. Continuous variables were
summarised by mean and standard deviation, with difference
between two independent groups performed using the unpaired stu-
dent T-test, and between multiple groups using 1-way analysis of
variance. Correlations were assessed using Spearman’s test.
2.3. Ethics
The study commenced following ethical approval by Sheffield
Teaching Hospital (protocol number: STH20572) and the Health
Research Authority (IRAS project ID: 253210). The study was done in
accordance with the STROBE statement.
2.4. Role of funder
This study was carried out independently and did not receive
funding.
3. Results
3.1. Study participants
Complete baseline demographic and symptom data was obtained
from 300 of 310 patients who attended for a 75SeHCAT retention test.
We subsequently excluded 116 patients from further analysis as they
disclosed risk factors for secondary BAD, as shown in the study flow
chart (Fig. 1).
The remaining 184 patients (female 65%, mean-age 47yrs, white
race 94%) were of interest, to assess for the possibility of primary
BAD, as they had symptoms consistent with chronic diarrhoea which
was presumed to be of functional origin, i.e. either functional diar-
rhoea or IBS-diarrhoea.
3.2. Prevalence of primary BAD in patients with chronic diarrhoea of
presumed functional origin
Following a 75SeHCAT test the prevalence of primary BAD in
patients with chronic diarrhoea of presumed functional origin was
38% (n = 70/184); of these, 53% (n = 37) had mild disease, 23% (n = 16)
had moderate disease, and 24% (n = 17) had severe disease.
Subjects with primary BAD were significantly more likely to have
a higher BMI and report increased stool frequency than those without
BAD, but otherwise no significant differences were seen in basic dem-
ographics, mood scores, somatic severity, or abdominal discomfort or
pain frequency (Table 1). There was also no difference seen in clinical
characteristics according to the severity of primary BAD (Table 2).
We further scrutinised the relationship between frequency of
mushy or loose watery stool and 75SeHCAT value, noting a negative
correlation (r=0.18, p = 0.001). With regards to BMI, we noted a)
that it was negatively associated with 75SeHCAT values (r=0.37, p
<0.0001) and b) that prevalence of Primary BAD increased from ~20%
in those who were underweight to almost 60% in those classed as
obese (p<0.0001); Fig. 2.
3.3. Prevalence of primary BAD according to Rome III and Rome IV
criteria
The number of patients fulfilling symptom criteria for Rome III
chronic diarrhoea disorders was 173 cases for IBS-diarrhoea and 11
cases for functional diarrhoea. Following a 75SeHCAT retention test,
the prevalence of primary BAD in this Rome III defined sample was
36% (n = 63/173) in IBS-diarrhoea and 64% (n = 7/11) in functional
diarrhoea; p = 0.11. The presence of BAD in Rome III IBS-diarrhoea
was mild in 18.5%, moderate in 9%, and severe in 9%. The presence of
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BAD in Rome III functional diarrhoea was mild in 45%, moderate in
9%, and severe in 9%.
When the Rome IV criterion was applied to the same cohort, the
number of patients with suspected IBS-diarrhoea was 139, a significant
reduction of 34 cases (20%) from the 173 IBS-diarrhoea cases under
Rome III classification; p<0.0001. Instead, the remaining 34 cases ful-
filled criteria from Rome IV functional diarrhoea, leading to the num-
ber of cases to rise from 11 (under Rome III) to 45. The prevalence of
primary BAD in this Rome IV defined sample was 38% (n = 53/139) in
IBS-diarrhoea and 38% (n = 17/45) in functional diarrhoea; p = 0.97.
The presence of BAD in Rome IV IBS-diarrhoea was mild in 19%, mod-
erate in 9%, and severe in 11%. The presence of BAD in Rome III func-
tional diarrhoea was mild in 24%, moderate in 9%, and severe in 4%.
Fig. 3 summarises the prevalence of primary BAD according to
Rome III and Rome IV criteria. This shows no difference in the preva-
lence of primary BAD from Rome III to Rome IV criteria for IBS-diar-
rhoea, which was 36% and 38% (p = 0.8), respectively. There was a
non-significant reduction of primary BAD from Rome III to Rome IV
functional diarrhoea, which was 60% and 38% respectively (p = 0.18),
although the former was limited by a relatively small sample size.
3.4. Prevalence of primary BAD according to the frequency of abdominal
pain
We found there to be no association between the frequency of
abdominal pain and the prevalence of primary BAD, with values ranging
between 25% and 50% (p = 0.36, Fig. 4). Moreover, the differing severities
of BADwere present regardless of abdominal pain frequency.
4. Discussion
This study builds on the existing literature, whereby a systematic
review found that in excess of a quarter of patients with symptoms
compatible with IBS-diarrhoea have primary BAD [6]. However, these
findings were based on historic Rome I-III criteria and extrapolating
to Rome IV required clarification given that the latter criteria for IBS
has undergone substantial modifications and is characterised by fre-
quent abdominal pain. The association between primary BAD and
abdominal pain has previously been conflicting [ 3,1214], thereby
potentially leaving physicians in uncertainty as to the role of primary
BAD in those with Rome IV IBS-diarrhoea. By undertaking a large
observational study we have shown that over a third of patients with
symptoms compatible with either functional diarrhoea or IBS-diar-
rhoea have primary BAD, a finding seen across both the Rome III and
Rome IV criteria. Moreover, almost half of cases with primary BAD
were categorised as being moderate to severe. In summary, these
findings confirm that primary BAD is common, and generic testing
for its possibility should be considered in patients presenting to sec-
ondary care settings with chronic diarrhoea of presumed functional
origin regardless of whether or not they have abdominal pain.
Strengths of the study include its large sample, prospective
recruitment, patients being referred for SeHCAT test by different
physicians from across the hospital trust, careful exclusion of organic
disease, and being the first to evaluate the prevalence of primary BAD
using the Rome III and Rome IV criteria in tandem. However, a poten-
tial weakness that may be attributed to our study is its generalisabil-
ity or selection bias given that patients were recruited within the
Fig. 1. Study flow chart.
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Nuclear Medicine department having been referred specifically for
the evaluation of primary BAD, and the results may not be applicable
to most patients with chronic diarrhoea seen in the out-patient clinic
setting. We acknowledge that this is a reasonable argument in pri-
mary care where there is no data on the prevalence of primary BAD.
However, we believe this argument can be refuted within secondary
care settings on the basis of the previously mentioned systematic
review [6] and in particular from a large prospective dual-centre out-
patient secondary-care study conducted within the UK, which found
that a third of all consecutive patients with Rome III IBS-diarrhoea
referred for a 75SeHCAT had primary BAD [20]. Similarly, a study
from the United States reported that 38% of patients with IBS-diar-
rhoea had increased levels of serum bile acid precursors compared
with healthy controls [21]. More recently, a large retrospective study
from the United States found that of 936 patients with chronic unex-
plained diarrhoea, over 50% had increased faecal bile acid excretion
whilst, in comparison, other diagnostic tests performed for organic
diseases (e.g. endoscopies and cross-sectional radiological imaging)
had a yield of less than 10% [22]. Finally, most Rome III-positive IBS
patients seeking healthcare fulfil Rome IV IBS criteria [23], suggesting
that the high prevalence rates of primary BAD reported for Rome III
can be transferred over to Rome IV; in our study, 80% of patients with
Rome III IBS retained the diagnosis under Rome IV whilst the other
20% were reassigned as functional diarrhoea.
Our study strongly supports recent international guidelines from
the United Kingdom, Canada and the United States that are promoting
increased awareness of primary BAD [79]. The potential scale of this
disorder may be estimated from a large survey across these 3 countries
which has shown that approximately 5% (i.e. 1-in-20) of adults within
the general population fulfil symptom criteria for either Rome IV func-
tional diarrhoea or IBS-diarrhoea [11]. Unfortunately, the high gastro-
intestinal illness burden and associated poor quality of life reported by
such individuals is despite many having previously sought healthcare
for their symptoms [11]. A recently published worldwide study, per-
formed across 30 countries and six continents, has yielded similar
results [24]. However, it could be argued that over of third of these
Table 1
Characteristics of individuals with primary BAD compared to those without.
Baseline characteristics No BAD (n = 114) Primary BAD (n = 70) P value
Demographics
Female 78 (68%) 41 (59%) 0.2
Mean age (SD) 47 (18) 48 (15) 0.7
White race 107 (94%) 66 (94%) 0.9
Smoker 18 (16%) 15 (21%) 0.4
Alcohol intake 74 (65%) 50 (71%) 0.4
Mean BMI (SD) 26 (5.9) 30 (6) <0.0001
Symptoms
Abnormal HADS-anxi-
ety score
42 (37%) 29 (42%) 0.5
Abnormal HADS-
depression score
19 (17%) 14 (20%) 0.6
High PHQ-12 somatisa-
tion score
18 (16%) 12 (17%) 0.8
Abdominal discomfort
 One day per month 4 (3.5%) 8 (11.4%)
Two-three days per
month
4 (3.5%) 1 (1.4%)
One day per week 3 (2.6%) 3 (4.3%) 0.3
Two-three days per
week
29 (25.4%) 11 (15.7%)
Most days 21 (27.2%) 17 (24.3%)
Everyday 19 (16.7%) 13 (18.6%)
Multiple times per day 24 (21.1%) 17 (24.3%)
Abdominal pain
 One day per month 14 (12.3%) 10 (14.3%)
Two-three days per
month
14 (12.3%) 7 (10%)
One day per week 9 (7.9%) 4 (5.7%) 0.3
Two-three days per
week
27 (23.7%) 9 (12.9%)
Most days 25 (21.9%) 21 (30%)
Everyday 16 (14%) 8 (11.4%)
Multiple times per day 9 (7.9%) 11 (15.7%)
% of stools reported as
mushy or watery
loose (SD)
66% (25) 76% (21) 0.01
Table 2
Characteristics of individuals with primary BAD stratified according to severity.
Baseline characteristics Mild BAD (n = 37) Moderate BAD (n = 16) Severe BAD (n = 17) P value
Demographics
Female 20 (54%) 9 (56%) 12 (71%) 0.6
Mean age (SD) 48 (16) 52 (13.5) 44 (13) 0.3
White race 36 (97%) 16 (100%) 14 (82%) 0.1
Smoker 8 (22%) 3 (19%) 4 (24%) 1.0
Alcohol intake 26 (70%) 13 (81%) 11 (65%) 0.6
Mean BMI (SD) 30 (6.7) 28 (5.3) 31 (4.7) 0.5
Symptoms
Abnormal HADS-anxiety score 17 (47%) 5 (31%) 7 (42%) 0.6
Abnormal HADS-depression score 6 (17%) 5 (31%) 3 (18%) 0.45
High PHQ-12 somatisation score 8 (22%) 2 (12.5%) 2 (12%) 0.7
Abdominal discomfort
 One day per month 6 (16.2%) 1 (6.3%) 1 (5.9%)
Two-three days per month 0 (0%) 1 (6.3%) 0 (0%)
One day per week 3 (8.1%) 0 (0%) 0 (0%)
Two-three days per week 7 (18.9%) 1 (6.3%) 3 (17.6%) 0.9
Most days 7 (18.9%) 5 (31.3%) 5 (29.4%)
Everyday 5 (13.5%) 4 (25%) 4 (23.5%)
Multiple times per day 9 (24.3%) 4 (25%) 4 (23.5%)
Abdominal pain
 One day per month 6 (16.2%) 2 (12.6%) 2 (11.8%)
Two-three days per month 5 (13.5%) 2 (12.5%) 0 (0%)
One day per week 2 (5.4%) 1 (6.3%) 1 (5.9%)
Two-three days per week 6 (16.2%) 0 (0%) 3 (17.6%) 0.75
Most days 11 (29.7%) 4 (25%) 6 (35.3%)
Everyday 3 (8.1%) 3 (18.8%) 2 (11.8%)
Multiple times per day 4 (10.8%) 4 (25%) 3 (17.6%)
% of stools reported as mushy or watery loose (SD) 72% (24) 81% (21) 80% (16) 0.2
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individuals may have primary BAD instead, which would imply that an
estimated 1.5% of the general population are suffering from the condi-
tion. Hence, testing for primary BAD is important given that it is com-
mon, frequently overlooked, and detrimentally impacts on physical
and mental well-being, with open-label treatment leading to
improved patient-related outcomes and a reduction in the number of
subsequent diagnostic investigations [3,22,2527]. Unfortunately,
testing modalities for primary BAD are not readily available across the
globe. Currently, the 75SeHCAT test is available in the United Kingdom,
certain European countries, and Canada, but not in the United States
where some centres test for BAD via alternate means, for example,
serum bile acid precursors (i.e. 7a‑hydroxy‑4-cholesten-3-one) ormea-
surement of faecal bile acids following a 48-hour stool collection [28].
There have been recent advances in developing a simple, cheap, and
readily available biomarker to screen for BAD, with promising data for
serum FGF19 or detection of volatile organic compounds (presumed to
be due to dysbiosis of colonic bile acids), however all require further
validation [2830].
In the meantime, some clinicians without resources to test for BAD
may consider a therapeutic trial of a bile acid sequestrant [31]. This
approach may be limited by the palatability of bile acid sequestrant and
Fig. 2. Evaluating the association between BMI and primary BAD in patients with chronic diarrhoea of presumed functional origin. A) The correlation between BMI and 75SeHCAT
result. B) The prevalence of primary BAD according to weight category.
Fig. 3. Prevalence of primary BAD in patients fulfilling symptom criteria for IBS-diar-
rhoea and functional-diarrhoea, based on Rome III and Rome IV criteria.
Fig. 4. Prevalence of primary BAD in patients with chronic diarrhoea of presumed functional origin, according to the frequency of abdominal pain.
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clinical uncertainty regarding diagnosis [32]. In such circumstances,
selecting the patient with the highest pre-test probability of primary BAD
may be a thoughtful option, with our data suggesting thosewho are over-
weight or obese as potentially reasonable candidates in view of the prev-
alence of primary BAD in this cohort reaching almost 60%. Previous
studies have also shown a link between increasing BMI and primary BAD
although unlike ours  have not performed direct comparisons of BAD
prevalence rates in patients with chronic diarrhoea stratified according to
the World Health Organisation weight classification system [20,21,33].
The link between increasing BMI and primary BAD is intriguing, with a
recent systematic review and meta-analysis confirming altered bile acid
metabolism in obesity [34]. This is evidenced by individuals with obesity
having lower serum FGF19, elevated serum bile acid precursors,
increased bile acid synthesis and luminal excretion, with shorter colonic
transit times [3,21,3335]. The pathophysiological basis for this associa-
tion is unclear, although some plausible explanations have been provided.
There is data showing FGF19 to increasemetabolic rates inmousemodels
[36]; therefore, deficient FGF19 levels could theoretically lead to a lower
metabolic rate and subsequently cause obesity. However, conversely, a
rise in FGF19 levels has been noted following bariatric surgery [37]. Fur-
ther mechanistic insights into this association are needed and - from a
clinical perspective - it would of interest to establish whether targeting
obesity can be considered a therapeutic option in primary BAD. Current
treatment options for BAD are limited to bile acid sequestrants or a low
fat diet, albeit hampered by a paucity of randomised controlled trials.
This is clearly an exciting area for future research.
In conclusion, over a third of subjects with Rome IV defined IBS-
diarrhoea or functional diarrhoea referred for a 75SeHCAT retention
test have primary BAD, similar to the Rome III criteria. Testing for pri-
mary BAD should be considered in patients with chronic diarrhoea of
presumed functional origin irrespective of associated abdominal pain.
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